gbola amusa md cfa head hc research
sale trade et
sale trade et
viral news genet medicin mgtx/qure/rgnx chardan top pick
highlight week januari januari buy announc unaudit
global revenu mm rnai-bas therapeut onpattro patient us eu receiv
commerci product revenu exceed mm audent therapeut
neutral announc plan dose earli addit patient part cohort expans arm phase
i/ii aspiro trial aav-bas gene therapi gt x-link myotubular myopathi xlmtm
compani also announc new asset develop larg neuromuscular indic audent
plan provid program overview voyag neutral provid updat guidanc vy-
aadc aav-basedgt treat parkinson diseas base feedback type meet fda
compani expand phase ii trial patient conduct staggered-
parallel phase studi similar size design reduc pt await visibl data
trial made buy uniqur buy chardan top pick join
buy name includ genet medicin alpha portfolio chardan genet medicin
top pick vintag gener averag alpha respect
weekli price move vivo genet medicin aav srna vivo gene edit notabl
upcom chardan genet medicin event contact chardan rsvp
analyst taylor feehley phd moder kol call featur patent attorney discuss ip issu
microbiom medicin space issu may relev genet medicin buy
januari synthet biolog genet medicin kolcal professor jame collin phd
analyst gbola amusa md cfa taylor feehley phd moder kolcal featur dr jame collin
discuss emerg switch technolog synthet biolog tool genet medicin space
analyst gbola amusa md cfa moder panel pm entitl improv cell therapi via
gener technolog summit
march chardan sponsor gene therapi genom edit summit host orphan diseas
march chardan sponsor arm cell gene therapi investor day new york citi
april chardan sponsor arm meet mediterranean barcelona
gene express uc berkeley publish protease-activat
articl publish januari journal cell crispr pioneer jennif doudna phd togeth scientist
uc berkeley gladston institut introduc structur rearrang rna-guid nucleas
allow dna cut activ turn specif signal cell normal alway
readi cut stretch dna sequenc match bound guid rna constitut activ limit abil
induc cut specif cell type tissu order reduc potenti safeti concern relat unwant
edit effort control cut focus place control promot
specif particular tissu place control promot switch activ small
molecul and/or deliv nucleas directli particular tissu eye
cell studi took altern innov approach call protein circular permut cp studi author
rearrang protein chain link begin part protein n-terminu end protein
c-terminu use short peptid linker chain open chain elsewher protein creat new
pleas refer import disclosur inform regul analyst certif found page report
n- c- termini abl engin variant remain inact peptid linker
chain cut proteas enzym unleash activ type regul natur use bodi
control activ blood clot factor digest enzym enzym exist inact form call pro-
enzym activ cut vari sequenc peptid linker produc variant
could activ differ type proteas includ medically-import sourc flavivirus
enabl use system readout viral infect technolog modifi respond
signal cell broadli framework engin novel fusion protein studi author envis
technolog could incorpor crispr-bas drug discoveri workflow well enhanc safeti
therapeut crispr applic approach align increas interest see use switch technolog
control activ express therapeut protein trend expect continu
buy chardan top pick reiter high convict januari
reiter high-convict buy rate made meiragtx chardan top pick base
see interest single-stock clinic catalyst aav-bas gt space
reiter reason meira high convict pick meira differ phase i/ii readout indic
new addit program clinic under-appreci bn market opportun
radiation-induc xerostomia align sever meira program predict chardan gene
therapi framework meira rapid progress de-risk manufactur access switch technolog
qure buy chardan top pick januari
made uniqur chardan top pick base
 compani best-in-class profil aav-bas gt hemophilia one largest
orphan drug market one uniqur import ip fix-padua
 uniqur manufactur provid flexibl abil gener revenu extern parti
 uniqur exposur advanc gt technolog engin transgen promot
 likelihood uniqur acquir possibl unrat biomarin base variou synergi relat
support uniqur like first best market aav-bas hemophilia gt given
 impress respons seen compani phase iib dose-confirm data
 low preval neutral antibodi nab potenti provid util patient
 regulatori design btd prime associ speed alpha gener gt space
chardan genet medicin alpha portfolio gmap articul convict view sector
close long foreign-gene-therapi basket/short nasdaq-biotechnology-index- nbi chardan genet
updat chardan genet medicin alpha portfolio gmap perform follow
medicin pair trade posit alpha gener sinc decemb market close
 chardan top pick genet medicin cumul alpha gener sinc march
 chardan genet medicin top pick close averag alpha gener
 chardan genet medicin top pick close averag alpha gener
genet medicin news januari januari
neutral provid pipelin outlook januari
neutral announc guidanc pipelin includ gt asset januari
prqr buy announc agreement fda piii design rna tx sepofarsen januari
unrat appoint dr philip vicker board director januari
neutral provid updat vy-aadc gt program pd type meet januari
voyag januari announc updat guidanc aav-bas gt vy-aadc base
feedback decemb type meet fda call compani conduct two adequ
well-control clinic trial larg patient popul parkinson diseas
page
compani plan submit revis trial protocol increas patient number
phase ii trial conduct staggered-parallel phase studi
rais pt june grant rmat design vy-aadc roughli
return pre-rmat pt reduc pt
maintain neutral rate see visibl perform voyag near
catalyst us fundament valuat pt unlik realiz come year
mdco buy announc idmc recommend continu piii inclisiran studi januari
buy initi dose pi studi rnai tx dyslipidemia januari
buy file applic begin pi studi rnai tx hypertriglyceridemia januari
apic privat rais mm seri develop rare genet diseas januari
unrat outlin anticip mileston pku cancer program januari
adap unrat advanc liver lung cancer studi safeti review januari
unrat initi first-in-human studi dna-encod monoclon ab zika viru januari
cyad unrat outlin prioriti focu car-t tx r/r aml januari
ortx unrat outlin strateg prioriti ex vivo lentivir gt program januari
bold neutral highlight recent progress delin prioriti januari
audent therapeut plan provid detail potenti registr pathway aav gt
treat x-link myotubular myopathi xlmtm initi interact fda ema recal
rmat prime design afford increas regulatori interact
next data readout xlmtm program expect annual meet american societi
gene cell therapi asgct may compani plan dose addit patient cohort
expans phase i/ii aspiro trial earli
beyond xlmtm audent plan file ind pomp diseas advanc new aav
gt asset larg neuromuscular diseas signific unmet medic need therapeut
target addit program detail disclos
unrat announc collabor inhibrx privat develop sdab-bas car-t januari
onsc unrat collabor gog foundat studi tavo keytruda cc januari
unrat outlin progress anticip mileston across gt ge program januari
announc achiev corpor goal posit begin phase i/ii trial
gt adult phenylketonuria pku data anticip later year
homolog nomin develop candid next indic aavhsc-bas nuclease-
free vivo gene edit asset pediatr pku cns-direct aavhsc-bas gt late-infantil
form metachromat leukodystrophi mld current ind-en studi
manufactur homolog complet build intern gmp facil design support
product gt ge program initi bioreactor scale
rgl nr nomin oligonucleotide-bas tx clinic candid gbm januari
buy announc global net product revenu mm onpattro januari
announc unaudit global revenu onpattro mm exceed
chardan project mm recal alnylam announc onpattro approv august
us eu treatment polyneuropathi hereditari transthyretin-medi hattr amyloidosi
patient us eu receiv commerci onpattro year-end total patient
world-wide treat patisiran includ clinic trial alnylam expand access program
compani establish value-bas agreement vba us payor negoti addit
us payor potenti cover percent commerci live us
buy plan initi patient screen pi/ii trial vivo ge tx januari
unrat outlin corpor highlight strateg plan across pipelin januari
unrat appoint dr mark pykett cso dr neil almstead januari
page
unrat provid updat program gt manufactur statu januari
locat privat receiv us patent intrastem intracellular deliveri technolog januari
adagen privat announc collabor nih novel car-t target januari
celg unrat announc anticip mileston provid financi guidanc januari
unc publish studi clearanc neuroblastoma mice car-t express januari
amyt gb unrat present preclin data topic non-vir gt januari
unrat provid updat rare diseas immuno-oncolog program januari
unrat begin patient recruit pi studi anti-bcma car-t mm januari
unrat appoint christin silverstein cfo edward cao januari
curevac privat receiv us patent mrna vaccin rsv infant januari
crsp buy appoint senior fda legisl offici john martin head govern affair januari
fda announc new offic focu biomark bioinformat pt-report outcom januari
 drug administr via fda commission scott gottlieb announc plan addit new
offic drug develop scienc goal advanc key scientif area order increas predict
drug develop modern drug review process
addit new offic part broader reorgan offic new drug area focu
group includ develop valid biomark bioinformat inform technolog
incorpor patient-report outcom structur safeti efficaci data area
repres subdivis new offic
us move surpris given agenc posit gestur modern drug review process
last year includ decemb issuanc draft guidanc biomark
nk unrat launch trial off-the-shelf nk cell tx superagonist ici mcc januari
sln gb unrat announc immedi departur cfo david ellam januari
unrat partner sirion biotech privat aav tx neurodegen diseas januari
nr announc data pi trial inhibitor cobomarsen cancer januari
uc berkeley publish cell protease-activat nucleas januari
compani mention report
page
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ adhera therapeut
benitec biopharma fibrocel buy lysogen oncosec medic oxford biomedica buy vbl neutral
figur select price movement week end januari vivo gm perform driven srna
page
week-over-week perform vivo genet medicin aav small rna vivo gene edit basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap genet medicin vivo cap genet medicin ex vivo cap gene therapytickerratingccm ptupsideclosechang changemc mm appli genet rna therapytickerratingccm ptupsideclosechang changemc mm alnylam gene editingtickerratingccm ptupsideclosechang changemc mm crispr pharmaceut
vivo genet medicin monthli market cap progress select compani
corpor report factset chardan note although avx acquir continu includ exhibit reflect valu creation sub-sector
figur aav-bas gene therapyend-monthli market cap select compani januari present
figur small rna therapyend-monthli market cap select compani januari present
figur vivo gene editingend-monthli market cap select compani januari present
page
cap million aav gt sector market cap cap million srna gt sector market cap cap million vivo gene edit sector market cap
aav-bas gene therapi comp meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap uncov name model current market cap
refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public aav-bas gene therapi companiesw prefer buy nite buy buy buy qure buy greater potenti drive upsid aav gt space
page
targettargetccmphas ofpric ccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof genet technolog privat aav-bas genetherapi molecular askbio estev horama myonexu tamid
small rna therapi comp alnylam top pick srna gene therapi offer favor risk-reward dynam
corpor report factset chardan note mention stock unrat unless state target market cap uncov name rgl silenc model current market cap
figur select public small rna therapi companiesw prefer buy greater potenti drive upsid entir small rna space
page
targettargetccmphas ofpric ccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat small rna therapi companiesadvirna silense sirnaom somagen sylentisnot adhera benitec biopharma addit unrat public compani
vivo gene edit comp see greater upsid potenti intellia toolgen
corpor report factset chardan note mention stock unrat unless otherwis state target market cap uncov name model current market cap
figur vivo gene editingw broadli expect out-performance crispr sector higher potenti perform buy toolgen buy
page
targettargetccmphas ofpric ccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitcrispr privat vivogen edit companiesbeam egenesi excis exon feldan poseida precis scienc recombinet
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
price prv
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
figur prioriti review voucher prv sold million million
page
date fda rpdd
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
page
date fda ftd
crispr vertex
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
